BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22012915)

  • 1. The ErbB4 extracellular region retains a tethered-like conformation in the absence of the tether.
    Liu P; Bouyain S; Eigenbrot C; Leahy DJ
    Protein Sci; 2012 Jan; 21(1):152-5. PubMed ID: 22012915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
    Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single ligand is sufficient to activate EGFR dimers.
    Liu P; Cleveland TE; Bouyain S; Byrne PO; Longo PA; Leahy DJ
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10861-6. PubMed ID: 22699492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation.
    Kani K; Park E; Landgraf R
    Biochemistry; 2005 Dec; 44(48):15842-57. PubMed ID: 16313187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.
    van der Woning SP; van Rotterdam W; Nabuurs SB; Venselaar H; Jacobs-Oomen S; Wingens M; Vriend G; Stortelers C; van Zoelen EJ
    J Biol Chem; 2006 Dec; 281(52):40033-40. PubMed ID: 17032651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.
    Shi F; Telesco SE; Liu Y; Radhakrishnan R; Lemmon MA
    Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7692-7. PubMed ID: 20351256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-induced structural transitions in ErbB receptor extracellular domains.
    Dawson JP; Bu Z; Lemmon MA
    Structure; 2007 Aug; 15(8):942-54. PubMed ID: 17697999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The single transmembrane domains of ErbB receptors self-associate in cell membranes.
    Mendrola JM; Berger MB; King MC; Lemmon MA
    J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
    Zhang X; Pickin KA; Bose R; Jura N; Cole PA; Kuriyan J
    Nature; 2007 Nov; 450(7170):741-4. PubMed ID: 18046415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.
    Garrett TP; McKern NM; Lou M; Elleman TC; Adams TE; Lovrecz GO; Kofler M; Jorissen RN; Nice EC; Burgess AW; Ward CW
    Mol Cell; 2003 Feb; 11(2):495-505. PubMed ID: 12620236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.
    Ward MD; Leahy DJ
    J Biol Chem; 2015 Jan; 290(3):1570-9. PubMed ID: 25468910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
    Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM
    Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-conserved features associated with cis regulation of ErbB tyrosine kinases.
    Mirza A; Mustafa M; Talevich E; Kannan N
    PLoS One; 2010 Dec; 5(12):e14310. PubMed ID: 21179209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
    Jura N; Shan Y; Cao X; Shaw DE; Kuriyan J
    Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21608-13. PubMed ID: 20007378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.
    Franco-Gonzalez JF; Ramos J; Cruz VL; Martínez-Salazar J
    J Mol Model; 2013 Feb; 19(2):931-41. PubMed ID: 23090500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis.
    Jones JT; Ballinger MD; Pisacane PI; Lofgren JA; Fitzpatrick VD; Fairbrother WJ; Wells JA; Sliwkowski MX
    J Biol Chem; 1998 May; 273(19):11667-74. PubMed ID: 9565587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
    Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
    Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
    Lu C; Mi LZ; Schürpf T; Walz T; Springer TA
    J Biol Chem; 2012 Nov; 287(45):38244-53. PubMed ID: 22988250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.